Practical Review of the Current Management of Fournier’s Gangrene

• Published in: Plastic and reconstructive surgery. Global open 2022-03, Vol.10 (3), p.e4191-e4191
• Main Authors: Huayllani, Maria T., Cheema, Amandip S., McGuire, Matthew J., Janis, Jeffrey E.
• Format: Article
• Language: English
• Subjects: Reconstructive; Review
• ISSN: 2169-7574; 2169-7574
• DOI: 10.1097/GOX.0000000000004191

Fournier's gangrene is a fulminant disease. If diagnosed and treated early, mortality can be minimized, but morbidity can still be important with extensive soft tissue defects affecting form and function. We aimed to perform a comprehensive review and provide the current evidenced-based management to treat this condition. A review was conducted to identify relevant published articles involving Fournier's gangrene in PubMed on September 8, 2021. Search keywords included "{[(Fournier's gangrene) AND (reconstruction)] OR [Fournier's gangrene]} AND [(repair) OR (management)]." A total of 108 articles met the inclusion criteria. The comorbidities most frequently associated included diabetes, hypertension, and obesity. Pillars of treatment involve urgent debridement, fluid resuscitation, IV antibiotics, and reconstruction. Several variables must be considered, including time to debridement, duration of antibiotics, debridement, and an individualized approach to choose a reconstructive option. Skin grafts and multiple types of flaps are commonly used for reconstruction. Treatment of Fournier's gangrene should be initiated as early as possible. Surgeons' expertise, patient preference, and resources available are essential factors that should direct the election of reconstruction.